Abstract：Niemann-Pick disease type C (NPC) is an autosomal recessive lysosomal lipid storage disease associated with impaired intracellular cholesterol trafficking. A wide spectrum of clinical phenotype has been described, with a possible onset at all ages of life from the neonatal period to adulthood, more often in childhood. Typically, hepatosplenomegaly, dystaxia, dysphagia, dysarthria and dementia are presented in NPC patients. Neurologic symptoms vary according to the onset age, but prolonged neonatal cholestasis, splenomegaly, cataplexy and vertical supranuclear gaze palsy are more specific signs to the diagnosis of the disease. Impaired cholesterol trafficking and unesterified cholesterol accumulation in the late endosomes and lysosomals, as a results of mutations in NPC1 or NPC2 genes, are initial for the disease, and defective cellular autophagy, defective lysosomal calcium homeostasis and oxidative stress may all play roles in the physiological processes. The definite diagnosis requires demonstration of unesterified cholesterol accumulated in fibroblasts cultured from skin biopsies or of pathogenic mutation of NPC1/NPC2 genes. Miglustat, the only available treatment approved to date, can alleviate neurological symptoms and slow disease progression when administered earlier.
Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update[J]. Mol Genet Metab, 2012, 106(3): 330-344.
[3]
Mengel E, Klunemann HH, Lourenco CM, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description[J]. Orphanet J Rare Dis, 2013, 8: 166.
[4]
Wijburg FA, Sedel F, Pineda M, et al. Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C[J]. Neurology, 2012, 78(20): 1560-1567.
[5]
Oyama K, Takahashi T, Shoji Y, et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid[J]. Tohoku J Exp Med, 2006, 209(3): 263-267.
[6]
Greer WL, Riddell DC, Byers DM, et al. Linkage of Niemann-Pick disease type D to the same region of human chromosome 18 as Niemann-Pick disease type C[J]. Am J Hum Genet, 1997, 61(1): 139-142.
[7]
Millat G, Marçais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop[J]. Am J Hum Genet, 2001, 68(6): 1373-1385.
[8]
Storch J, Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking[J]. Biochim Biophys Acta, 2009, 1791(7): 671-678.
[9]
Abi-Mosleh L, Infante RE, Radhakrishnan A, et al. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells[J]. Proc Natl Acad Sci U S A, 2009, 106(46): 19316-19321.
[10]
Dixit SS, Jadot M, Sohar I, et al. Loss of Niemann-Pick C1 or C2 protein results in similar biochemical changes suggesting that these proteins function in a common lysosomal pathway[J]. PLoS One, 2011, 6(8): e23677.
[11]
Millat G, Marçais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop[J]. Am J Hum Genet, 2001, 68(6): 1373-1385.
[12]
Vanier MT, Wenger DA, Comly ME, et al. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients[J]. Clin Genet, 1988, 33(5): 331-348.
Xiong H, Higaki K, Wei CJ, et al. Genotype/phenotype of 6 Chinese cases with Niemann-Pick disease type C[J]. Gene, 2012, 498(2): 332-335.
[15]
Yang CC, Su YN, Chiou PC, et al. Six novel NPC1 mutations in Chinese patients with Niemann-Pick disease type C[J]. Neurol Neurosurg Psychiatry, 2005, 76(4): 592-595.
[16]
Millat G, Marçais C, Rafi MA, et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype[J]. Am J Hum Genet, 1999, 65(5): 1321-1329.
Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches[J]. J Neurochem, 2011, 116(5): 789-795.
[19]
Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations[J]. Neuropathol Exp Neurol, 2001, 60(1): 49-64.
[20]
te Vruchte D, Lloyd-Evans E, Veldman RJ, et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport[J]. Biol Chem, 2004, 279(25): 26167-26175.
[21]
Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism[J]. Int J Cell Biol, 2012, 2012: 282041.
[22]
Ravikumar B, Sarkar S, Davies JE, et al. Regulation of mammalian autophagy in physiology and pathophysiology[J]. Physiol Rev, 2010, 90(4): 1383-1435.
[23]
Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion[J]. Nature, 2008, 451(7182): 1069-1075.
[24]
Komatsu M. Liver autophagy: physiology and pathology[J]. J Biochem, 2012, 152(1): 5-15.
[25]
Sarkar S. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers[J]. Biochem Soc Trans, 2013, 41(5): 1103-1130.
[26]
Peake KB, Vance JE. Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice[J]. J Biol Chem, 2012, 287(12): 9290-9298.
[27]
Meske V, Erz J, Priesnitz T, et al. The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability[J]. J Neurobiol Dis, 2014, 64: 88-97.
[28]
Sarkar S, Carroll B, Buganim Y, et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease[J]. Cell Rep, 2013, 5(5): 1302-1315.
[29]
Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium[J]. Nat Med, 2008, 14(11): 1247-1255.
[30]
Vázquez MC, Balboa E, Alvarez AR, et al. Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease[J]. Oxid Med Cell Longev, 2012, 2012: 205713.
[31]
Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons[J]. Biochim Biophys Acta, 2004, 1685(1-3): 48-62.
Buard I, Pfrieger FW. Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells[J]. Mol Cell Neurosci, 2014, 61: 65-71.
[34]
Sarna JR, Larouche M, Marzban H, et al. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease[J]. J Comp Neurol, 2003, 456(3): 279-291.
[35]
Macauley SL, Sidman RL, Schuchman EH, et al. Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration[J]. Exp Neurol, 2008, 214(2): 181-192.
[36]
Yu T, Shakkottai VG, Chung C, et al. Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration[J]. Hum Mol Genet, 2011, 20(22): 4440-4451.
[37]
Lopez ME, Klein AD, Dimbil UJ, et al. Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder[J]. Neurosci, 2011, 31(12): 4367-4378.
[38]
Erickson RP. Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia[J]. Appl Genet, 2013, 54(2): 215-224.
[39]
Wraith JE, Sedel F, Pineda M, et al. Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations[J]. Inherit Metab Dis, 2014, 37(1): 93-101.
[40]
Rodrigues AF, Gray RG, Preece MA, et al. The usefulness of bone marrow aspiration in the diagnosis of Niemann-Pick disease type C in infantile liver disease[J]. Arch Dis Child, 2006, 91(10): 841-844.
[41]
Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update[J]. Mol Genet Metab, 2012, 106(3): 330-344.
[42]
Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease[J]. Sci Transl Med, 2010, 2(56): 56ra81.
[43]
Jiang X, Sidhu R, Porter FD, et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma[J]. Lipid Res, 2011, 52(7): 1435-1445.
[44]
Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C[J]. J Child Neurol, 2010, 25(3): 300-305.
[45]
Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial[J]. Mol Genet Metab, 2010, 99(4): 351-357.
[46]
Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study[J]. Lancet Neurol, 2007, 6(9): 765-772.
[47]
Pineda M, Wraith JE, Mengel E, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study[J]. Mol Genet Metab, 2009, 98(3): 243-249.
[48]
Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat treated patients[J]. Inherit Metab Dis, 2011, 34(5): 991-1001.
[49]
Champion H, Ramaswami U, Imrie J, et al. Dietary modifications in patients receiving miglustat[J]. Inherit Metab Dis, 2010, 33 Suppl 3: S379-S383.
[50]
Marín T, Contreras P, Castro JF, et al. Vitamin E dietary supplementation improves neurological symptoms and decreases c-Abl/p73 activation in Niemann-Pick C mice[J]. Nutrients, 2014, 6(8): 3000-3017.
[51]
Walterfang M, Chien YH, Imrie J, et al. Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat[J]. Orphanet J Rare Dis, 2012, 7: 76.
[52]
Rosenbaum AI, Cosner CC, Mariani CJ, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics[J]. Med Chem, 2010, 53(14): 5281-5289.
[53]
Abi-Mosleh L, Infante RE, Radhakrishnan A, et al. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells[J]. Proc Natl Acad Sci U S A, 2009, 106(46): 19316-19321.
[54]
Liu B, Ramirez CM, Miller AM, et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid[J]. Lipid Res, 2010, 51(5): 933-944.
Bonney DK, O'Meara A, Shabani A, et al. Successful allogeneic bone marrow transplant for Niemann-Pick disease type C2 is likely to be associated with a severe 'graft versus substrate' effect[J]. Inherit Metab Dis, 2010, 33 Suppl 3: S171-S173.
